Year:
Language:
Author(s): Federación mundial de hemofilia,factor de coagulación
Format: Document
Also Available In: Japanese
El tratamiento de personas con hemofilia con concentrado de factor derivado de plasma seguro y reglamentado reduce directamente el impacto social y económico que este trastorno de la coagulación tiene sobre el paciente y la cantidad de apoyo de largo plazo que se requiere de familiares, comunidad y gobierno.
A summary of discussions held at the Eleventh WFH Global Forum on Research and Treatment Products for Bleeding Disorders which
In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Johnny Mahlangu, David Page & Brian O’Mahony explore the
In this session from the WFH 2020 Virtual Summit, Radoslaw Kaczmarek, Flora Peyvandi, Dan Hart & Johnny Mahlangu discuss novel
In this session from the WFH 2020 World Summit, Glenn Pierce will examine the evolution of gene therapy while addressing
Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor
This module was presented by Susan Cutter at the Virtual Workshop for Psychosocial Professionals in Central and South America on